👉Hypocalcemia post total thyroidectomy – Anish Kolly et el May 2017 World Journal of Endocrine Surgery

👉The occurrence of hypocalcemia postthyroidectomy is a menacing condition and can be permanent in severe forms.

👉The extent of surgery, presence of Graves’ disease, technique of surgery, and the presence of preoperative vitamin D deficiency have all been proven to play a role in increasing the risk of postoperative hypocalcemia.

👉With the increasing trend of day-care surgeries and early discharge of patients postsurgery, the need of the hour is to evaluate for possible markers to aid in early prediction of postoperative hypocalcemia.

👉Preoperative vitamin D levels, pre- and postoperative iPTH measurement, and evaluation of trend of calcium changes postoperatively can all aid in the prediction of subsequent hypocalcemia. This can aid in selecting the patients at risk for developing hypocalcemia, in order to discharge calcium and active vitamin D replacement and to follow up accordingly.

👉The Tubercle of Zuckerkandl (TZ) is not only an important landmark, but also if not properly identified and carefully dissected, increases the chances of recurrent laryngeal nerve (RLN) injury. The new concept of a fascial plane separating the TZ and RLN reinforces the importance of identification TZ for safe dissection of the parathyroid glands and the RLN.

👉There is a fascial sleeve extending from the posterior ‘V’ lip of the superior pole of thyroid which passes posteriorly. This on anteromedial rotation becomes the superficial vascular fascial layer. This encloses the TZ.

👉Tubercle of Zuckerkandl is both the pointer to the RLN and also separates the superior and inferior parathyroid gland.

👉In this situation, it is necessary to mobilize TZ and also rotate it almost 180 degrees anteriorly and medially to expose the RLN and also for the safe dissection of parathyroid glands.

👉It works as a maker and a tool for safe thyroid surgery. In the changing paradigm of thyroid surgery, the TZ, which was an inconstant landmark has now become a constant landmark for identification of RLN.

👉The thyroid surgeon should be aware that it is more consistently found, usually larger on the right with anatomical variations and also might result in pressure symptoms especially in small goiters and becomes a friend as the surgeon experience increases.

👉Saba Retnam et al. World Journal of Endocrine Surgery May 2015

Vitamin D and Hypocalcemia- ATA meeting presentation 2014

Vit D deficiency is significantly associated with postoperative, symptomatic hypocalcemia in thyroid cancer patients undergoing TT plus CCND. In fact, vitamin D deficiency could predict symptomatic hypocalcemia in cases of postoperative iPTH levels <15 pg/mL,” said Nam. “We suggest that preoperative supplementation of oral vitamin D be considered as a way to minimize postoperative symptomatic hypocalcemia in thyroid cancer patients with preoperative vitamin D deficiency.”

Postoperative hypocalcemia is the most common complication after TT, with transient hypocalcemia occurring in about 30% to 50% of patients and permanent hypocalcemia, lasting 6 months or longer, occurring in 0.5% to 2% of patients. In addition to uncomfortable symptoms, postoperative hypocalcemia also results in longer hospital stays and ongoing laboratory tests.

👉COVIDSurg-Cancer & RECON
(REspiratory ComplicatiOns after abdomiNal surgery)

👉This study was a comparative analysis of the two international prospective cohort studies: one before the pandemic (RECON) and the second during the SARS-CoV-2 pandemic (COVIDSurg-Cancer). It is the first study able to directly compare death after pulmonary complications of surgery before and during the pandemic, including both the direct effect of SARS-CoV-2 and the collateral impact of the pandemic on the safety of elective surgery.

👉New publication that I had the opportunity to collaborate in.

• Thyroid nodules are exceedingly common:
  • With a reported prevalence between 19%to 68% in adults:
    • On high-resolution ultrasound
• Currently, fine-needle aspiration (FNA):
  • Is the most effective, practical test to determine whether a nodule is malignant or may require surgery to reach a definitive diagnosis
• Most thyroid nodules are benign, and even malignant nodules, particularly ones smaller than 1 cm, frequently exhibit indolent or nonaggressive behavior:
  • Therefore, not all detected nodules require FNA and / or surgery
• Despite a rapid increase in the reported incidence of papillary thyroid cancer (PTC) that resulted from screening thyroid sonography in asymptomatic patients in South Korea:
  • Mortality has remained extremely low
• In the United States, over-diagnosis of thyroid cancer:
  • Defined as “diagnosis of thyroid tumors that would not, if left alone, result in symptoms or death”:
    • Accounted for 70% to 80% of thyroid cancer cases in women and 45% of cases in men between 2003 and 2007:
      • Therefore, a reliable, noninvasive method to identify which nodules warrant FNA on the basis of a reasonable likelihood of biologically significant malignancy would be highly desirable
• In 2015, committees convened by the ACR published white papers:
  • That presented an approach to incidental thyroid nodules and proposed standard terminology (lexicon) for ultrasound reporting
• Project Rationale and Consensus Process:
  • Several professional societies and groups of investigators have proposed methods to guide ultrasound practitioners in recommending FNA on the basis of ultrasound features
  • Some of these systems were termed TI-RADS (Thyroid Imaging, Reporting and Data System):
    • Because they were modeled on the ACR’s BI-RADS^®, which has been widely accepted in breast imaging
  • Other societies, such as the American Thyroid Association (ATA):
    • Have taken a slightly different, pattern-oriented approach, but with the same intent
  • The plethora, complexity, and lack of congruence of these systems has limited their adoption by the ultrasound community and inspired our effort to publish a classification system under the auspices of the ACR
  • The ACR TI-RADS Committee agreed on the following attributes for our risk classification algorithm. It would be:
    • Founded on the ultrasound features defined in there previously published lexico
    • Easy to apply across a wide gamut of ultrasound practices
    • Able to classify all thyroid nodules
    • Evidence based to the greatest extent possible
  • The proposals presented in this white paper, which were developed via conference calls, e-mail, and online surveys, represent the consensus opinion of the ACR TI-RADS Committee:
    • They are based on the literature; analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute
    • Evaluation of existing risk classification systems; and expert opinion
    • Our recommendations are intended to serve as guidance for practitioners who incorporate ultrasound in the management of adult patients with thyroid nodules
    • They should not be construed as standards
    • Interpreting and referring physicians are legally and professionally responsible for applying their professional judgment to every case, regardless of the ACR TI-RADS recommendations
    • The decision to perform FNA should also account for:
      • The referring physician’s preference and the patient’s risk factors for thyroid cancer, anxiety, comorbidities, life expectancy, and other relevant considerations
• Overview of ACR TI-RADS:
  • The ultrasound features in the ACR TI-RADS are categorized as:
    • Benign
    • Minimally suspicious for malignancy
    • Moderately suspicious for malignancy
    • Highly suspicious for malignancy
  • Points are given for all the ultrasound features in a nodule:
    • With more suspicious features being awarded additional points
  • Figure 1 presents these features arranged per the five lexicon categories
  • When assessing a nodule:
    • The reader selects one feature from each of the first four categories and all the features that apply from the final category and sums the points
    • The point total determines the nodule’s ACR TI-RADS level:
      • Which ranges from TR1 (benign) to TR5 (high suspicion of malignancy)
        • Note that although it is possible for a nodule to be awarded zero points and hence be characterized as TR1:
          • All other nodules merit at least two points because a nodule that has a mixed cystic and solid composition (one point) will also gain at least one more point for the echogenicity of its solid component
  • Finally, although sonoelastography is a promising technique, it is probably not available in many ultrasound laboratories and is not incorporated into the ACR TI-RADS
  • In the ACR TI-RADS, recommendations for FNA or ultrasound follow-up:
    • Are based on a nodule’s ACR TI-RADS level and its maximum diameter
  • For risk levels TR3 through TR5:
    • The chart presents a size threshold at or above which FNA should be recommended
    • They also defined lower size limits for recommending follow-up ultrasound for TR3, TR4, and TR5 nodules to limit the number of repeat sonograms for those that are likely to be benign or not clinically significant
  • In developing the ACR TI-RADS, the committee strived to account for the discrepancy between the sharp rise in the diagnosis and treatment of thyroid cancer resulting from increased detection and biopsy and the lack of commensurate improvement in long-term outcomes
  • This suggested that diagnosing every thyroid malignancy should not be our goal
  • Like other professional societies:
    • The ACR TIRADS recommend biopsy of high-suspicion nodules only if they are 1 cm or larger
    • As well, they advocate biopsy of nodules that have a low risk for malignancy only when they measure 2.5 cm or more
  • The ACR TI-RADS is designed to balance the benefit of identifying clinically important cancers against the risk and cost of subjecting patients with benign nodules or indolent cancers to biopsy and treatment
  • There recommendations for follow-up ultrasound substantially mitigate the possibility that significant malignancies will remain undetected over time and are concordant with the increasing trend toward active surveillance (“watchful waiting”) for low-risk thyroid cancer
• Differences Between ACR TI-RADS and Other Systems:
  • Structure:
    • To make the system easy to understand and apply, the ACR TI-RADS does not include:
      • Subcategories, nor does it include a TR0 category to indicate a normal thyroid gland
    • The ACR TI-RADS also lends itself to implementation as templates in voice recognition reporting or computerized decision support systems
    • The committee decided against the pattern-based approach used by the ATA on the basis of the results of a study by Yoon et al:
      • Which showed that the ATA guidelines:
        • Were unable to classify 3.4% of 1,293 nodules:
          • Of which 18.2% were malignant
        • Notably, that study included only nodules that were subjected to FNA or surgery
        • It is likely that an even greater percentage of nodules would not have been categorized had other nodules been included, as it is not practical to provide patterns that account for every potential constellation of features
• Size Thresholds for FNA:
  • The ACR TI-RADS is consistent with most other guidelines:
    • In recommending FNA for highly suspicious nodules 1 cm or larger:
  • However, thresholds for mildly suspicious and moderately suspicious nodules (2.5 and 1.5 cm, respectively):
    • Are higher than the cutoffs advocated by the ATA and the Korean Society of Thyroid Radiology
  • In a 2005 publication cited by both organizations, Machens et al:
    • Contended that the cumulative risk for distant metastases from papillary and follicular thyroid cancer:
      • Rose at a threshold of 2 cm
    • They therefore advocated biopsy of nodules larger than 2 cm
      • However, reviewing their graphs suggested a gradual, slight increase that began at a larger size
    • More important, Machens et al based their analysis on tumor size in resected specimens, not on ultrasound dimensions
  • Subsequent research has demonstrated a significant lack of concordance between sonographic and pathologic sizing:
    • With a tendency for ultrasound to result in larger measurements
    • Of 205 papillary carcinomas ≥ 1.5 cm studied by Bachar et al:
      • The mean diameter on ultrasound was 2.65 ± 1.07 cm, compared with 1.97 ± 1.17 cm on pathology
  • The committee’s higher size cutoffs reflect this discrepancy:
    • ACR further guided by evaluation of a database of more than 3,000 proven thyroid nodules that was created for a study sponsored by the Society of Radiologists in Ultrasound:
      • Partial analysis showed cancer risk levels of:
        • No more than 2% for TR1 and TR2 nodules
        • 5% for TR3 nodules
        • 5% to 20% for TR4 nodules
        • At least 20% for TR5 nodules
    • They also considered published and SEER data analyses:
      • That showed a slight increase in distant metastases:
        • At 2.5 cm
      • As well as slight increments in 10-year relative and thyroid cancer-specific mortality:
        • At 3 cm
• ACR TI-RADS Feature Categories:
  • Composition:
    • Nodules that are cystic or almost completely cystic merit no points because they are almost universally benign
    • A spongiform architecture is highly correlated with benign cytology:
      • Regardless of its relative echogenicity or other features
      • However, a spongiform nodule must be composed predominantly (greater than 50%) of small cystic spaces
      • Nodules should not be characterized as spongiform solely on the basis of the presence of a few, scattered cystic components in an otherwise solid nodule
    • “Mixed cystic and solid” combines two features from the lexicon, predominately solid and predominately cystic
    • The appearance of the solid component is more important than the overall size of the nodule or the proportion of solid versus cystic components:
      • In determining whether biopsy is warranted
    • Solid material that is eccentric and has an acute angle with the nodule’s wall is suspicious, as is:
      • Solid material with moderately or highly suspicious characteristics, such as:
        • Decreased echogenicity
        • Lobulation
        • Punctate echogenic foci
    • As well, although color Doppler ultrasound has not been shown to reliably discriminate between benign and malignant nodules:
      • The presence of flow in solid components:
        • Distinguishes tissue from echogenic debris or hemorrhage:
          • Inconsequential debris may be identified by:
            • Layering or motion elicited by changes in patient position

• Echogenicity:
  • This feature refers to a nodule’s reflectivity relative to adjacent thyroid tissue:
    • Except for very hypoechoic nodules:
      • In which the strap muscles are used as the basis for comparison
  • This category also includes “anechoic,” a zero-point feature that was absent from the lexicon:
    • It applies to cystic or almost completely cystic nodules that would otherwise be given three points because of their very hypoechoic appearance
• Shape:
  • A taller-than-wide shape:
    • Is an insensitive but highly specific indicator of malignancy:
      • This feature is evaluated in the axial plane:
        • By comparing the height (“tallness”) and width of a nodule measured parallel and perpendicular to the ultrasound beam, respectively
        • A taller-than-wide configuration is usually evident on visual inspection and rarely requires formal measurements
• Margin:
  • The presence of a halo is neither discriminatory nor mutually exclusive with other margin types; therefore, they elected to omit it
  • They included “ill defined” in this group so that any reporting template that incorporates a field for margin will not be left empty if a nodule is not well defined.
  • “Lobulated or irregular margin”:
    • Refers to a spiculated or jagged edge, with or without protrusions into the surrounding parenchyma
    • It may be difficult to recognize this finding if the nodule is:
      • Ill defined, is embedded in a heterogeneous gland, or abuts multiple other nodules
    • If the margin cannot be determined for any reason, zero points should be assigned
    • Extension beyond the thyroid border is classified as:
      • Extensive or minimal:
        • We use the term border because the thyroid gland lacks a true fibrous capsule
        • Extensive extra-thyroidal extension (ETE):
          • That is characterized by frank invasion of adjacent soft tissue and / or vascular structures:
            • Is a highly reliable sign of malignancy and is an unfavorable prognostic sign
        • Minimal ETE may be suspected sonographically in the presence of:
          • Border abutment
          • Contour bulging
          • Loss of the echogenic thyroid border
        • However, agreement among pathologists for identification of minimal ETE is poor, and its clinical significance is controversial:
          • Therefore, practitioners should exercise caution when reporting minimal ETE, particularly for otherwise benign-appearing nodules
• Echogenic Foci:
  • “Large comet-tail artifacts” are:
    • Echogenic foci with V-shaped echoes greater than 1 mm deep to them
    • They are associated with colloid and are strongly indicative of benignity when found within the cystic components of thyroid nodules
  • “Macro-calcifications” are:
    • Coarse echogenic foci accompanied by acoustic shadowing
    • Evidence in the literature regarding their association with increased malignancy risk is mixed, especially in nodules lacking other malignant features
    • Given published data that show a weakly positive relationship with malignancy:
      • Macro-calcifications are assigned one point, recognizing that the risk is increased if the nodule also contains moderately or highly suspicious features that warrant additional points
    • Peripheral calcifications:
      • Lie along all or part of a nodule’s margin
      • Their correlation with malignancy in the literature is variable
      • However, because some publications suggest that they are more strongly associated with malignancy than macro-calcifications, they are awarded two points
      • Some authors have called attention to interrupted peripheral calcifications with protruding soft tissue as suspicious for malignancy, but with low specificity
      • In the ACR TI-RADS, this appearance qualifies as a lobulated margin:
        • Which adds another two points to the nodule’s total assignment
    • In nodules with calcifications that cause strong acoustic shadowing that precludes or limits assessment of internal characteristics, particularly echogenicity and composition:
      • It is best to assume that the nodule is solid and assign two points for composition and one point for echogenicity
    • Punctate echogenic foci are smaller than macro-calcifications and are non-shadowing:
      • In the solid components of thyroid nodules, they may correspond to the psammomatous calcifications associated with papillary cancers and are therefore considered highly suspicious, particularly in combination with other suspicious features
      • This category includes echogenic foci that are associated with small comet-tail artifacts in solid components:
        • As distinguished from the large comet-tail artifacts described earlier
      • Notably, small echogenic foci may be seen in spongiform nodules:
        • Where they probably represent the back walls of minute cysts
        • They are not suspicious in this circumstance and should not add to the point total of spongiform nodules
• Additional Benign Appearances:
  • Several ultrasound findings have been described as characteristic of benign nodules with a high degree of reliability
  • These include:
    • A uniformly hyperechoic (“white knight”) appearance
    • A variegated pattern of hyperechoic areas separated by hypoechoic bands reminiscent of giraffe hide:
      • Both in the setting of Hashimoto’s thyroiditis
    • Because of their scarcity, the committee chose not to formally incorporate these patterns in the ACR TI-RADS chart
• Papillary Thyroid Micro-carcinomas:
  • The ACR TI-RADS is concordant with other guidelines in recommending against routine biopsy of nodules smaller than 1 cm:
    • Even if they are highly suspicious
  • However, because some thyroid specialists advocate active surveillance, ablation, or lobectomy for papillary microcarcinomas:
    • Biopsy of 5 mm to 9 mm TR5 nodules may be appropriate under certain circumstances
    • The determination to perform FNA will involve shared decision making between the referring physician and the patient
    • The report should indicate whether the nodule can be measured reproducibly on follow-up studies
    • Additionally, nodules in critical submarginal locations may complicate surgery:
      • Therefore, the report should also indicate whether the nodule abuts the trachea or whether it is adjacent to the tracheoesophageal groove (the location of the recurrent laryngeal nerve)
• Reporting Considerations:
  • Measurement and Documentation:
    • Accurate sizing of thyroid nodules is critical, as the maximum dimension determines whether a given lesion should be biopsied or followed
    • Although some interobserver discrepancy is inevitable because of variable conspicuity, consistent technique improves measurement accuracy and reproducibility
    • Nodules should be measured in three axes:
      • Maximum dimension on an axial image
      • Maximum dimension perpendicular to the previous measurement on the same image
      • Maximum longitudinal dimension on a sagittal image
    • For obliquely oriented nodules, these measurements may be different than the ones used to determine a taller-than-wide shape, but this discrepancy should rarely present a problem in practice
    • Measurements should also include:
      • The nodule’s halo, if present
    • Practitioners may use linear dimensions to determine volume, a calculation that is available on many ultrasound machines
    • Regardless of the method used, each practice should measure and report nodules consistently to facilitate serial comparison

• Definition of Growth:
  • Criteria for significant growth depend on:
    • The size of the nodule and must take measurement variability into account
  • In the ACR TI-RADS, significant enlargement is defined as:
    • A 20% increase in at least two nodule dimensions and a minimal increase of 2 mm, or
    • A 50% or greater increase in volume, as in the criteria adopted by other professional societies
  • Because enlargement may not be apparent if the current sonogram is compared only with the immediately preceding one, it is important to also review measurements from earlier scans, if available
• Timing of Follow-Up Sonograms:
  • There is little consensus in the literature regarding optimal spacing of follow-up sonograms for nodules that do not meet size criteria for FNA, as growth rates do not reliably distinguish benign from malignant nodule
  • The committee believes that scanning intervals of less than 1 year are not warranted:
    • Except for proven cancers under active surveillance, which may require more frequent follow-up at the discretion of the referring physician
  • We advocate timing on the basis of a nodule’s ACR TI-RADS level, with additional sonograms for lesions that are more suspicious:
    • For a TR5 lesion, we recommend scans every year for up to 5 years
    • For a TR4 lesion, scans should be done at 1, 2, 3, and 5 years
    • For a TR3 lesion, follow-up imaging may be performed at 1, 3, and 5 years
    • Imaging can stop at 5 years if there is no change in size, as stability over that time span reliably indicates that a nodule has a benign behavior
  • There is no published evidence to guide management of nodules that enlarge significantly but remain below the FNA size threshold for their ACR TI-RADS level at 5 years, but continued follow-up is probably warranted
  • If a nodule’s ACR TI-RADS level increases on follow-up, the next sonogram should be done in 1 year, regardless of its initial level
• Number of Nodules to Biopsy:
  • Biopsy of three or more nodules is poorly tolerated by patients and increases cost with little or no benefit and some added risk
  • Therefore, the committee recommends targeting no more than two nodules with the highest ACR TI-RADS point totals that meet criteria for FNA
  • Size should not be the primary criterion for deciding which nodule(s) to sample
  • They discourage usage of the term dominant nodule, which is often applied to the largest lesion in the gland:
    • Because it downplays the primary role of architecture in determining management
  • If three or more nodules fall within ACR TI-RADS guidelines for biopsy, the two with the most suspicious appearance on the basis of point totals should be biopsied, even if they are not the largest
  • Conversely, in a gland that contains multiple discrete nodules that do not meet criteria, there is little reason to subject the largest one to FNA solely because of its size
  • Although malignancy cannot be definitively excluded under these conditions, sampling variation lessens the chance of detecting cancer because it would be impractical to biopsy every nodule
  • Likewise, biopsy is usually not indicated in a gland that is replaced by multiple, confluent nodules of similar appearance
• Assessment of Cervical Lymph Nodes:
  • Evaluation of cervical lymph nodes is a vital part of every thyroid sonographic examination
  • Abnormal findings suggestive of cervical lymph node metastasis include:
    • A globular shape
    • Loss of the normal echogenic hilum
    • Presence of peripheral rather than hilar flow
    • Heterogeneity with cystic components
    • Punctate echogenic foci that may represent microcalcifications
  • They recommend FNA of suspicious nodes, in addition to up to two nodules that warrant biopsy on the basis of the ACR TI-RADS

#Arrangoiz #Surgeon #ThyroidSurgeon #CancerSurgeon #ThyroidExpert #EndorineSurgery #HeadandNeckSurgeon

👉Anaplastic thyroid cancer
T4A- OS 15.8months
T4B- OS 6.1months
T4C – OS 2.8 months

Onoda N, Sugitani I, Ito KI, Suzuki A, Higashiyama T, Fukumori T, et al. Evaluation of the 8th edition TNM classification for anaplastic thyroid carcinoma. Cancers. 2020;12:1–11.

https://thyroidresearchjournal.biomedcentral.com/articles/10.1186/s13044-020-00091-w#ref-CR5

Clasificación TIRADS

TIRADS classification 

Rodrigo Arrangoiz MS, MD, FACS cirujano de tumores de cabeza y cuello / cirugia endocrina / cirugía oncológica es experto en el manejo de patología  de la glándula tiroides.

Su entrenamiento fue el siguiente:

• Cirugia general y gastrointestinal:
• Michigan State University:
• 2004 al 2010• Cirugia oncológica / tumores de cabeza y cuello / cirugia endocrina:
• Fox Chase Cancer Center (Filadelfia):
• 2010 al 2012• Maestria en ciencias (Clinical research for healthprofessionals):
• Drexel University (Filadelfia):
• 2010 al 2012• Cirugia de tumores de cabeza y cuello / cirugiaendocrina
• IFHNOS / Memorial Sloan Kettering Cancer Center:
• 2014 al 2016

https://file.scirp.org/pdf/IJOHNS_2017072615211601.pdf

https://file.scirp.org/pdf/IJOHNS_2018071317420392.pdf

• Clin Thyroidol 2021;33:484–486.
• The evaluation of patients with thyroid nodules requires adequate stratification to estimate the risk of thyroid cancer:
  • Evaluation also requires an understanding of the patient’s situation
• To assist clinicians in this task, multiple thyroid nodule sonographic risk-stratification systems (RSSs) have been developed, including:
  • The American Thyroid Association (ATA) system
  • The American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS)
  • The Korean Thyroid Imaging Reporting and Data System (K-TIRADS)
  • The European Thyroid Imaging Reporting and Data System (EU-TIRADS)
  • The Artificial Intelligence Thyroid Imaging Reporting and Data System (AI TI-RADS)
• In general, studies assessing the performance of these RSSs have been retrospective and have included patients who have undergone a diagnostic intervention (i.e., thyroid nodule biopsy or surgery):
  • This type of study design can introduce bias into the assessment of diagnostic properties by increasing the proportion of high risk cases
• Although RSSs for thyroid nodules aim to standardize thyroid cancer risk assessment and recommendations:
  • The ACR TI-RADS is associated with a lower number of recommendations for thyroid biopsy:
    • This is due, in part, to the system’s relatively more conservative thresholds for recommending thyroid biopsy
• In the current study, a comparison of thyroid nodule RSSs is evaluated:
  • In thyroid nodule risk distribution in an unselected group of patients undergoing thyroid ultrasound
  • By assessing the impact of risk distribution, in addition to the size thresholds, on biopsy recommendations
• Methods:
  • This was a multi-institutional study of seven radiology practices that participate in the ACR registry
  • Each practice prospectively submitted thyroid ultrasound reports on adult patients between October 2018 and March 2020
  • Sites provided the maximum size of the thyroid nodules and followed structured reporting according to the five ACR TI-RADS ultrasound features
  • Patients with thyroid cancer, nodule size less than 5 mm or greater than 5 cm, and incomplete / unrealistic data were excluded
  • The submitted reports were then retrospectively categorized following the criteria of ACR TI-RADS, the ATA system, K-TIRADS, EU-TIRADS, and AI TI-RADS
  • The distribution of risk categories and thyroid biopsy recommendation rates were compared
  • Because of the large sample size, even small differences in the proportions observed were expected to be statistically significant
• Results:
  • The study population consisted of:
    • 12,208 patients, mostly women (84%), encompassing a total of 27,933 thyroid nodules
  • The mean patient age was 60.7 years, and the mean (±SD) nodule size was 1.5 ± 0.92 cm
  • There were 1896 nodules that could not be classified according to the ATA system
  • According to ACR TI-RADS:
    • The distribution of thyroid nodules was:
      • TIRADS 1 (TR1) (3.1%), TR2 (8.2%), TR3 (31.0%), TR4 (48.3%), and TR5 (9.4%)
  • The ACR TI-RADS and AI TI-RADS:
    • Placed more nodules in the TR2 category (8.2% and 10%, respectively) than the other systems (range, 1.2%–2.5%)
  • EU-TIRADS:
    • Placed more nodules in the high suspicion / TR5-equivalent category (18.9%) than did the other systems (range, 9.1–12.5%)
  • AI TI-RADS had the lowest level of TR3 nodules (26.1%) as compared with the other systems (range, 31–44.4%)
  • In all, the most common category for all nodules was TR4 and its equivalents (42.1–48.3%)
  • ACR TI-RADS recommended biopsies in 29.1% of the thyroid nodules:
    • One of the lowest rates as compared with other systems (ATA, 58.7%; EU-TIRADS, 38.9%; K-TIRADS, 57%)
    • AI TI-RADS recommended biopsy for 26.3% of the nodules
  • Finally, when evaluating thyroid biopsy recommendations according to risk category:
    • The rate of recommended biopsy was similar in the TR5 categories and equivalents (68.7–75.5%)
  • There was variability for TR2:
    • With ACR TI-RADS recommending biopsy in 0% of the nodules (range for others, 2.8–17.7%)
  • The largest differences were for TR3 and TR4 nodules:
    • For which ACR TI-RADS and AI TI-RADS recommended biopsy in 19.0% to 22.3% and 32.7% to 33.7 %, respectively; the range for the other systems was 33.3 to 53.7% for TR3 and 29.0 to 64.0% for TR4
  • Conclusions:
    • Differences in the distribution of sonographic thyroid nodule risk categories and biopsy size thresholds among the various RSSs contribute to variability in clinical recommendations for thyroid biopsies
    • ACR TI-RADS generally recommends a lower number of biopsies:
      • Because of a combination of its risk assignment criteria and more conservative biopsy thresholds
  • This large multi-center study validates the clinical utility of thyroid nodule risk stratification:
    • By evaluating patients who underwent thyroid ultrasound regardless of their diagnostic workup
  • Using ACR TI-RADS, 11.3% of the thyroid nodules were considered either benign or very low risk for thyroid cancer, while 9.4% were considered high risk
  • Most patients had nodules considered either T3 or T4 (31.0% and 48.3%, respectively)
  • This distribution highlights the importance of high-quality ultrasound risk stratification in the evaluation of patients with thyroid nodules, as it can facilitate reassurance in patients with low-risk nodules
  • Similarly, a robust RSS may appropriately justify the consideration of biopsy in those at higher ris
  • In addition, the study evaluated the impact of size thresholds across the different risk categories to guide the need for thyroid biopsies
  • Application of ACR TI-RADS was associated with a biopsy rate of 29.1%:
    • Lower than that for all the other systems except for AI TI-RADS
  • This was driven, in part:
    • By fewer biopsy recommendations for nodules in categories TR3 and TR4
    • As well as a greater proportion of nodules in the TR2 category:
      • For which biopsy is not recommended
  • Taken together, these findings suggest that, in addition to different size thresholds for biopsy, the distribution of risk categories affects biopsy recommendation rates
  • In fact, the overall proportion of nodules recommended for biopsy varied between the systems, from 26.3% in AI TI-RADS to 58.7% in the ATA system
  • These findings highlight the urgent need for and value of current efforts to harmonize thyroid nodule RSSs, particularly in terms of risk-category definitions and management recommendations by malignancy estimates and size thresholds for biopsy
  • This endeavor might be challenging, given that clinical evidence that can guide the selection of biopsy size thresholds is limited
  • More importantly, in this large study, most nodules were categorized as TR3 or TR4, and overall the mean nodule size was 1.5 cm, representing a group of patients in whom management recommendations by the major RSSs are highly variable
  • These findings underscore the value of a care model that uses the best available evidence to understand thyroid cancer risk and supports the collaboration of patients and clinicians when deciding how to respond to this risk

#Arrangoiz #ThyroidSurgeon #CancerSurgeon #ThryoidExpert #ThyroidNodules #ThyroidCancer #Miami

-Mirizzi syndrome is subclassified in to 5 types :

🔴𝗜: Is obstruction of the extrahepatic bile duct stone/s in the Hartmann’s pouch or cystic duct.

🔴𝗜𝗜: Is with a cholecystocholedochal fistula (diameter < 1/3 or the common hepatic duct wall).

🔴𝗜𝗜𝗜: Is with a cholecystocholedochal fistula (diameter < 2/3 of the common hepatic duct wall).

🔴𝗜𝗩: Is with a cholecystocholedochal fistula (involving the whole common hepatic duct wall).

🔴𝗩: Any type associated with a cholecystoenteral fistula (i.e,fistula to stomach, duodenum or hepatic flexure or transverse colon). This is sometimes sub-classiied depending on whether gallstone ileus is present or not.

𝙍𝙚𝙛:Difficult Acute Cholecystitis Treatment and Technical Issues,1st ed. 2021© Springer.

#Arrangoiz #Surgeon #CASO #Miami #CenterforAdvancedSurgicalOncology